TIDMEMIS
RNS Number : 3082L
EMIS Group PLC
18 July 2017
18 July 2017
EMIS Group plc
("EMIS Group" or "the Group")
Restatement of segmental reporting
EMIS Group plc (AIM: EMIS.L), the UK leader in connected
healthcare software and services, today announces its restated
segmental reporting.
Overview
Since 2013 the Group has presented its results split into three
segments: Primary & Community Care; Community Pharmacy; and
Secondary & Specialist Care. As previously announced, the
Primary & Community Care and Secondary (Acute) Care businesses
are now under common leadership, and Patient has been established
as a separate entity. The directors therefore consider the
following segmental split to represent better the Group's present
structure, activities and the markets being served:
-- Primary, Community & Acute Care
-- Community Pharmacy
-- Specialist & Care
-- Patient
This split reflects how the business is managed and reported
internally. Tables setting out the previous and new segmental
reporting for the 2016 comparative periods are provided below. With
the exception of the previous segmental numbers for the year ended
31 December 2016, which have been extracted from the audited 2016
Annual Report and Accounts, the numbers are unaudited.
Segmental reporting for half year
Previous segmental New segmental
Six months ended Six months ended
30 June 2016 30 June 2016
Primary,
Primary Secondary Community
& Community Community & Specialist & Acute Community Specialist
Care Pharmacy Care Total Care Pharmacy & Care Patient Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Revenue 48,983 10,348 19,339 78,670 60,256 10,348 7,046 1,020 78,670
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Segmental
operating
profit
as reported
internally 14,745 2,214 1,469 18,428 15,298 2,214 369 547 18,428
Development
costs
capitalised 1,052 895 935 2,882 1,987 895 - - 2,882
Amortisation of
development
costs (2,315) - (646) (2,961) (2,961) - - - (2,961)
Amortisation of
acquired
intangible
assets (527) (288) (2,505) (3,320) (2,702) (288) (330) - (3,320)
Cost reduction
programme (412) (107) (1,633) (2,152) (1,894) (107) (151) - (2,152)
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Segmental
operating
profit/(loss) 12,543 2,714 (2,380) 12,877 9,728 2,714 (112) 547 12,877
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Group operating
expenses (736) (736)
Operating profit 12,141 12,141
Net finance
costs (231) (231)
Share of result
of joint
venture 271 271
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Profit before
taxation 12,181 12,181
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Segmental reporting for full year
Previous segmental New segmental
Year ended Year ended
31 December 2016 31 December 2016
Primary,
Primary Secondary Community
& Community Community & Specialist & Acute Community Specialist
Care Pharmacy Care Total Care Pharmacy & Care Patient Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Revenue 99,615 21,425 37,672 158,712 120,565 21,425 14,163 2,559 158,712
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Segmental
operating
profit
as reported
internally 32,202 4,876 3,292 40,370 33,792 4,876 213 1,489 40,370
Development
costs
capitalised 1,882 1,927 1,875 5,684 3,757 1,927 - - 5,684
Amortisation of
development
costs (4,497) - (1,516) (6,013) (6,013) - - - (6,013)
Amortisation of
acquired
intangible
assets (1,054) (576) (5,009) (6,639) (5,405) (576) (658) - (6,639)
Cost reduction
programme (1,162) (140) (2,328) (3,630) (2,707) (140) (783) - (3,630)
Impairment of
goodwill - - (4,616) (4,616) - - (4,616) - (4,616)
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Segmental
operating
profit/(loss) 27,371 6,087 (8,302) 25,156 23,424 6,087 (5,844) 1,489 25,156
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Group operating
expenses (1,617) (1,617)
Operating profit 23,539 23,539
Net finance
costs (237) (237)
Share of result
of joint
venture 499 499
Gain on sale of
associate 1,532 1,532
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
Profit before
taxation 25,333 25,333
---------------- ------------ --------- ------------- ------- ---------- --------- ---------- ------- -------
For further information, contact:
EMIS Group plc Tel: 0113 380 3000
Andy Thorburn, CEO
Peter Southby, CFO
www.emisgroupplc.com
Numis Securities Limited (Nominated Adviser & Broker) Tel: 020 7260 1000
Oliver Hardy/Simon Willis/James Black
MHP Communications Tel: 020 3128 8540
Reg Hoare/Giles Robinson/Charlie Barker
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUUWMUPMGMM
(END) Dow Jones Newswires
July 18, 2017 02:00 ET (06:00 GMT)
Emis (LSE:EMIS)
Historical Stock Chart
From Apr 2024 to May 2024
Emis (LSE:EMIS)
Historical Stock Chart
From May 2023 to May 2024